Clara R Farley1, Shelby Irwin1, Taiwo Adesoye1, Susie X Sun1, Sarah M DeSnyder1, Anthony Lucci1, Simona F Shaitelman2, Edward I Chang3, Naoto T Ueno4, Wendy A Woodward2, Mediget Teshome5. 1. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Plastic and Reconstructive Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mteshome@mdanderson.org.
Abstract
BACKGROUND: Breast cancer-related lymphedema (BCRL) is a debilitating sequela of breast cancer treatment and is becoming a greater concern in light of improved long-term survival. Inflammatory breast cancer (IBC) is a rare and aggressive malignancy for which systemic therapy, surgery, and radiotherapy remain the standard of care, thereby making IBC patients highly susceptible to developing BCRL. This study evaluated BCRL in IBC following trimodal therapy. METHODS: IBC patients treated from 2016 to 2019 were identified from an institutional database. Patients were excluded if they presented with recurrent disease, underwent bilateral axillary surgery, did not complete trimodal therapy, or were lost to follow-up. Demographic, clinicopathologic factors, oncologic outcomes, and perometer measurements were recorded. BCRL was defined by clinician diagnosis and/or objective perometer measurements when available. Time to development of BCRL and treatment received were captured. RESULTS: Eighty-three patients were included. Median follow-up was 33 months. The incidence of BCRL was 50.6% (n = 42). Mean time to BCRL from surgery was 13 (range 2-24) months. Demographic and clinicopathologic features were similar between patients with and without BCRL with exception of higher proportion receiving delayed reconstruction in the BCRL group (38.1% vs. 14.6%, p = 0.03). Forty patients (95.2%) underwent BCRL treatment, which included physical therapy (n = 39), compression (n = 38), therapeutic lymphovenous bypass (n = 13), and/or vascularized lymph node transfer (n = 12). CONCLUSIONS: IBC patients are at high-risk for BCRL after treatment, impacting 51% of patients in this cohort. Strategies to reduce or prevent BCRL and improve real-time diagnosis should be implemented to better direct early management in this patient population.
BACKGROUND: Breast cancer-related lymphedema (BCRL) is a debilitating sequela of breast cancer treatment and is becoming a greater concern in light of improved long-term survival. Inflammatory breast cancer (IBC) is a rare and aggressive malignancy for which systemic therapy, surgery, and radiotherapy remain the standard of care, thereby making IBC patients highly susceptible to developing BCRL. This study evaluated BCRL in IBC following trimodal therapy. METHODS: IBC patients treated from 2016 to 2019 were identified from an institutional database. Patients were excluded if they presented with recurrent disease, underwent bilateral axillary surgery, did not complete trimodal therapy, or were lost to follow-up. Demographic, clinicopathologic factors, oncologic outcomes, and perometer measurements were recorded. BCRL was defined by clinician diagnosis and/or objective perometer measurements when available. Time to development of BCRL and treatment received were captured. RESULTS: Eighty-three patients were included. Median follow-up was 33 months. The incidence of BCRL was 50.6% (n = 42). Mean time to BCRL from surgery was 13 (range 2-24) months. Demographic and clinicopathologic features were similar between patients with and without BCRL with exception of higher proportion receiving delayed reconstruction in the BCRL group (38.1% vs. 14.6%, p = 0.03). Forty patients (95.2%) underwent BCRL treatment, which included physical therapy (n = 39), compression (n = 38), therapeutic lymphovenous bypass (n = 13), and/or vascularized lymph node transfer (n = 12). CONCLUSIONS: IBC patients are at high-risk for BCRL after treatment, impacting 51% of patients in this cohort. Strategies to reduce or prevent BCRL and improve real-time diagnosis should be implemented to better direct early management in this patient population.
Authors: Shane R Stecklein; Kelly J Rosso; Jenny Nuanjing; Audree B Tadros; Anna Weiss; Sarah M DeSnyder; Henry M Kuerer; Mediget Teshome; Thomas A Buchholz; Michael C Stauder; Naoto T Ueno; Anthony Lucci; Wendy A Woodward Journal: Pract Radiat Oncol Date: 2019-05-24
Authors: Rebecca J Tsai; Leslie K Dennis; Charles F Lynch; Linda G Snetselaar; Gideon K D Zamba; Carol Scott-Conner Journal: Ann Surg Oncol Date: 2009-04-14 Impact factor: 5.344
Authors: Shaheenah Dawood; Yun Gong; Kristine Broglio; Thomas A Buchholz; Wendy Woodward; Anthony Lucci; Vicente Valero; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Massimo Cristofanilli Journal: Breast J Date: 2010-07-06 Impact factor: 2.431
Authors: David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Joseph P Costantino; Takamaru Ashikaga; Donald L Weaver; Eleftherios P Mamounas; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh Mc Scarth; Norman Wolmark Journal: Lancet Oncol Date: 2010-10 Impact factor: 41.316
Authors: S Dawood; S D Merajver; P Viens; P B Vermeulen; S M Swain; T A Buchholz; L Y Dirix; P H Levine; A Lucci; S Krishnamurthy; F M Robertson; W A Woodward; W T Yang; N T Ueno; M Cristofanilli Journal: Ann Oncol Date: 2010-07-05 Impact factor: 32.976
Authors: Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi Journal: Lancet Oncol Date: 2013-03-11 Impact factor: 41.316
Authors: Chiaojung Jillian Tsai; Jing Li; Ana M Gonzalez-Angulo; Pamela K Allen; Wendy A Woodward; Naoto T Ueno; Anthony Lucci; Savitri Krishnamurthy; Yun Gong; Wei Yang; Massimo Cristofanilli; Vicente Valero; Thomas A Buchholz Journal: Am J Clin Oncol Date: 2015-06 Impact factor: 2.339
Authors: Kelly J Rosso; Audree B Tadros; Anna Weiss; Carla L Warneke; Sarah DeSnyder; Henry Kuerer; Naoto T Ueno; Shane R Stecklein; Wendy A Woodward; Anthony Lucci Journal: Ann Surg Oncol Date: 2017-08-01 Impact factor: 5.344